메뉴 건너뛰기




Volumn 2, Issue 6, 2010, Pages 1125-1140

Therapeutic monoclonal antibody concentration monitoring: Free or total?

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIIDIOTYPIC ANTIBODY; BASILIXIMAB; BEVACIZUMAB; CANAKINUMAB; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; RITUXIMAB; TRASTUZUMAB; ANTIGEN;

EID: 79951973140     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.64     Document Type: Review
Times cited : (80)

References (92)
  • 1
    • 60849128549 scopus 로고    scopus 로고
    • Monoclonal antibodies as innovative therapeutics
    • Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 9(6), 423-430 (2008).
    • (2008) Curr. Pharm. Biotechnol. , vol.9 , Issue.6 , pp. 423-430
    • Reichert, J.M.1
  • 2
    • 0001313220 scopus 로고
    • Thyroid function in nephrosis 1
    • Recant L, Riggs DS. Thyroid function in nephrosis 1. J. Clin. Invest. 31(8), 789-797 (1952).
    • (1952) J. Clin. Invest. , vol.31 , Issue.8 , pp. 789-797
    • Recant, L.1    Riggs, D.S.2
  • 3
    • 0001296463 scopus 로고
    • The interaction of thyroid hormones and protein in biological fluids
    • discussion 202-168
    • Robbins J, Rall J. The interaction of thyroid hormones and protein in biological fluids. Recent Prog. Horm. Res. 13, 161-202; discussion 202-168 (1957).
    • (1957) Recent Prog. Horm. Res. , vol.13 , pp. 161-202
    • Robbins, J.1    Rall, J.2
  • 4
    • 0015699481 scopus 로고
    • Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication
    • Booker HE, Darcey B. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia 14(2), 177-184 (1973).
    • (1973) Epilepsia , vol.14 , Issue.2 , pp. 177-184
    • Booker, H.E.1    Darcey, B.2
  • 5
    • 0021368529 scopus 로고
    • Rationale for monitoring free drug levels
    • Levy RH, Moreland TA. Rationale for monitoring free drug levels. Clin. Pharmacokinetics 9(Suppl. 1), 1-9 (1984). (Pubitemid 14179495)
    • (1984) Clinical Pharmacokinetics , vol.9 , Issue.SUPPL. 1 , pp. 1-9
    • Levy, R.H.1    Moreland, T.A.2
  • 6
    • 77956341588 scopus 로고    scopus 로고
    • Hardman JG Limbird LE Molinoff PB Ruddon RW Gilman AG Eds 9th Edition McGraw-Hill Companies NY USA
    • Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (Eds).Goodman and Gilman's the Pharmacological Basis of Therapeutics (9th Edition).McGraw-Hill Companies, NY, USA (1996).
    • (1996) Goodman and Gilmans the Pharmacological Basis of Therapeutics
  • 7
    • 0013531266 scopus 로고    scopus 로고
    • Theory of immunoassays
    • Diamandis EP Christopo TK Eds Elsevier Inc. San Diego CA USA
    • Christopoulos TK, Diamandis EP. Theory of immunoassays. In:Immunoassay. Diamandis EP, Christopo TK (Eds).Elsevier Inc., San Diego, CA, USA, 25-50 (1996).
    • (1996) Immunoassay , pp. 25-50
    • Christopoulos, T.K.1    Diamandis, E.P.2
  • 8
    • 46849108990 scopus 로고    scopus 로고
    • Introduction to immunoassay principles
    • 3rd Edition Wild D Ed Elsevier Kidlington Oxford UK
    • Davies C. Introduction to immunoassay principles. In:The Immunoassay Handbook (3rd Edition). Wild D (Ed.) Elsevier, Kidlington, Oxford, UK, 3-40 (2005).
    • (2005) Immunoassay Handbook , pp. 3-40
    • Davies, C.1
  • 10
    • 23844532353 scopus 로고    scopus 로고
    • Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy
    • DOI 10.1016/j.jim.2005.06.008, PII S0022175905001900
    • Hamilton RG, Marcotte GY, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J. Immunol. Methods 303(1-2), 81-91 (2005). (Pubitemid 41169948)
    • (2005) Journal of Immunological Methods , vol.303 , Issue.1-2 , pp. 81-91
    • Hamilton, R.G.1    Marcotte, G.V.2    Saini, S.S.3
  • 11
    • 66049094734 scopus 로고    scopus 로고
    • In vivo regulation of interleukin 1b in patients with cryopyrin-associated periodic syndromes
    • Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1b in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206(5), 1029-1036 (2009).
    • (2009) J. Exp. Med. , vol.206 , Issue.5 , pp. 1029-1036
    • Lachmann, H.J.1    Lowe, P.2    Felix, S.D.3
  • 13
    • 0034958819 scopus 로고    scopus 로고
    • Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis
    • DOI 10.1136/ard.60.7.660
    • Barrera P, Joosten LA, Den Broeder AA, Van De Putte LB, Van Riel PL, Van Den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor TNFa monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFa in patients with rheumatoid arthritis. Ann. Rheum. Dis. 60(7), 660-669 (2001). (Pubitemid 32588369)
    • (2001) Annals of the Rheumatic Diseases , vol.60 , Issue.7 , pp. 660-669
    • Barrera, P.1    Joosten, L.A.B.2    Den Broeder, A.A.3    Van De Putte, L.B.A.4    Van Riel, P.L.C.M.5    Van Den Berg, W.B.6
  • 14
    • 15244344037 scopus 로고    scopus 로고
    • On the prediction of the human response: A recycled mechanistic pharmacokinetic/pharmacodynamic approach
    • DOI 10.1111/j.1742-7843.2005.pto960307.x
    • Meno-Tetang GML, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/ pharmacodynamic approach. Basic Clin. Pharmacol. Toxicol. 96(3), 182-192 (2005). (Pubitemid 40387994)
    • (2005) Basic and Clinical Pharmacology and Toxicology , vol.96 , Issue.3 , pp. 182-192
    • Meno-Tetang, G.M.L.1    Lowe, P.J.2
  • 16
    • 0029411144 scopus 로고
    • Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation
    • Gijbels K, Brocke S, Abrams JS, Steinman L. Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol. Med. 1(7), 795-805 (1995). (Pubitemid 3013088)
    • (1995) Molecular Medicine , vol.1 , Issue.7 , pp. 795-805
    • Gijbels, K.1    Brocke, S.2    Abrams, J.S.3    Steinman, L.4
  • 17
    • 3142564395 scopus 로고    scopus 로고
    • Three new assays for rituximab based on its immunological activity or antigenic properties: Analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas
    • DOI 10.1016/j.jim.2004.03.012, PII S0022175904001206
    • Beum PV, Kennedy AD, Taylor RP. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Methods 289(1-2), 97-109 (2004). (Pubitemid 38900908)
    • (2004) Journal of Immunological Methods , vol.289 , Issue.1-2 , pp. 97-109
    • Beum, P.V.1    Kennedy, A.D.2    Taylor, R.P.3
  • 18
    • 79953662834 scopus 로고    scopus 로고
    • Comparison of a therapeutic target capture ligand-binding assay to an anti-idiotype capture sandwich ELISA
    • Spriggs F, Deng S, Soderstrom C, Aggarwal P, King L, Wang HF. Comparison of a therapeutic target capture ligand-binding assay to an anti-idiotype capture sandwich ELISA. AAPS J. 11(S1), 520 (2009).
    • (2009) AAPS J. , vol.11 , Issue.S1 , pp. 520
    • Spriggs, F.1    Deng, S.2    Soderstrom, C.3    Aggarwal, P.4    King, L.5    Wang, H.F.6
  • 19
    • 79953655047 scopus 로고    scopus 로고
    • Development of generic total assays for quantitation of therapeutic human IgG2 monoclonal antibodies in nonclinical species using ligand-binding assay
    • Guo J, King L, Wang HF. Development of generic total assays for quantitation of therapeutic human IgG2 monoclonal antibodies in nonclinical species using ligand-binding assay. AAPS J. 11(S1), 315 (2009).
    • (2009) AAPS J. , vol.11 , Issue.S1 , pp. 315
    • Guo, J.1    King, L.2    Wang, H.F.3
  • 21
    • 54249138516 scopus 로고    scopus 로고
    • Monoclonal antibody pharmacokinetics and pharmacodynamics
    • Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84(5), 548-558 (2008).
    • (2008) Clin. Pharmacol. Ther. , vol.84 , Issue.5 , pp. 548-558
    • Wang, W.1    Wang, E.Q.2    Balthasar, J.P.3
  • 23
    • 32444438731 scopus 로고    scopus 로고
    • Elimination mechanisms of therapeutic monoclonal antibodies
    • DOI 10.1016/S1359-6446(05)03638-X, PII S135964460503638X
    • Tabrizi MA, Tseng C-Ml, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 11(1-2), 81-88 (2006). (Pubitemid 43227856)
    • (2006) Drug Discovery Today , vol.11 , Issue.1-2 , pp. 81-88
    • Tabrizi, M.A.1    Tseng, C.-M.L.2    Roskos, L.K.3
  • 24
    • 0036882397 scopus 로고    scopus 로고
    • Protein ectodomain shedding
    • Arribas J, Borroto A. Protein ectodomain shedding. Chem. Rev. 102(12), 4627-4638 (2002).
    • (2002) Chem. Rev. , vol.102 , Issue.12 , pp. 4627-4638
    • Arribas, J.1    Borroto, A.2
  • 25
    • 20844454381 scopus 로고    scopus 로고
    • Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab
    • DOI 10.1038/nrd1752
    • Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4(6), 510-518 (2005). (Pubitemid 40861993)
    • (2005) Nature Reviews Drug Discovery , vol.4 , Issue.6 , pp. 510-518
    • Steinman, L.1
  • 26
    • 0033596831 scopus 로고    scopus 로고
    • A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
    • Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52(5), 1072 (1999).
    • (1999) Neurology , vol.52 , Issue.5 , pp. 1072
    • Sheremata, W.A.1    Vollmer, T.L.2    Stone, L.A.3    Willmer-Hulme, A.J.4    Koller, M.5
  • 27
    • 33646431420 scopus 로고    scopus 로고
    • Shedding of lymphocyte function-associated antigen-1 LFA-1 in a human inflammatory response
    • Evans BJ, Mcdowall A, Taylor PC, Hogg N, Haskard DO, Landis RC. Shedding of lymphocyte function-associated antigen-1 (LFA-1) in a human inflammatory response. Blood 107(9), 3593-3599 (2006).
    • (2006) Blood , vol.107 , Issue.9 , pp. 3593-3599
    • Evans, B.J.1    Mcdowall, A.2    Taylor, P.C.3    Hogg, N.4    Haskard, D.O.5    Landis, R.C.6
  • 30
    • 0028812791 scopus 로고
    • Mechanisms of action and overview of OKT3
    • Norman DJ. Mechanisms of action and overview of OKT3. Ther. Drug Monit. 17(6), 615-620 (1995).
    • (1995) Ther. Drug Monit. , vol.17 , Issue.6 , pp. 615-620
    • Norman, D.J.1
  • 31
    • 0028236071 scopus 로고
    • Variations in serum OKT3 concentration based upon age sex transplanted organ treatment regimen, and anti-OKT3 antibody status
    • Schroeder TJ, Michael AT, First MR et al. Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status. Ther. Drug Monit. 16(4), (1994).
    • (1994) Ther. Drug Monit. , vol.16 , pp. 4
    • Schroeder, T.J.1    Michael, A.T.2    First, M.R.3
  • 34
    • 0034770328 scopus 로고    scopus 로고
    • Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
    • DOI 10.1177/00912700122012751
    • Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol. 41(11), 1206-1214 (2001). (Pubitemid 32983219)
    • (2001) Journal of Clinical Pharmacology , vol.41 , Issue.11 , pp. 1206-1214
    • Dowell, J.A.1    Korth-Bradley, J.2    Liu, H.3    King, S.P.4    Berger, M.S.5
  • 35
    • 4544350808 scopus 로고    scopus 로고
    • Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
    • DOI 10.1517/14712598.4.9.1445
    • Damle NK. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin. Biol. Ther. 4(9), 1445-1452 (2004). (Pubitemid 39222977)
    • (2004) Expert Opinion on Biological Therapy , vol.4 , Issue.9 , pp. 1445-1452
    • Damle, N.K.1
  • 36
    • 58149331196 scopus 로고    scopus 로고
    • High shed antigen levels within tumors: An additional barrier to immunoconjugate therapy
    • Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin. Cancer Res. 14(24), 7981-7986 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , Issue.24 , pp. 7981-7986
    • Zhang, Y.1    Pastan, I.2
  • 37
    • 0023101978 scopus 로고
    • Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
    • Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69(2), 584-591 (1987). (Pubitemid 17022032)
    • (1987) Blood , vol.69 , Issue.2 , pp. 584-591
    • Press, O.W.1    Appelbaum, F.2    Ledbetter, J.A.3
  • 41
    • 4944220440 scopus 로고    scopus 로고
    • A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
    • DOI 10.1182/blood-2004-05-1733
    • Cragg MS, Bayne MB, Tutt AL et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 104(8), 2540-2542 (2004). (Pubitemid 39331858)
    • (2004) Blood , vol.104 , Issue.8 , pp. 2540-2542
    • Cragg, M.S.1    Bayne, M.B.2    Tutt, A.L.3    French, R.R.4    Beers, S.5    Glennie, M.J.6    Illidge, T.M.7
  • 42
    • 75749148026 scopus 로고    scopus 로고
    • Clinical response pharmacokinetics development of human anti-chimeric antibodies and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis
    • 10.1136/ard.2009.109041 Epub ahead of print
    • Thurlings RM, Teng O, Vos K et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. DOI:10.1136/ard.2009.109041 (2009) (Epub ahead of print).
    • (2009) Ann. Rheum. Dis.
    • Thurlings, R.M.1    Teng, O.2    Vos, K.3
  • 44
    • 33847257777 scopus 로고    scopus 로고
    • Pharmacokinetics of rituximab and its clinical use: Thought for the best use?
    • DOI 10.1016/j.critrevonc.2006.09.004, PII S1040842806002009
    • Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit. Rev. Oncology/Hematology 62(1), 43-52 (2007). (Pubitemid 46330791)
    • (2007) Critical Reviews in Oncology/Hematology , vol.62 , Issue.1 , pp. 43-52
    • Cartron, G.1    Blasco, H.2    Paintaud, G.3    Watier, H.4    Le Guellec, C.5
  • 45
    • 1842791537 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation
    • DOI 10.1016/j.ctrv.2003.10.003
    • Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat. Rev. 30(3), 255-268 (2004). (Pubitemid 38477271)
    • (2004) Cancer Treatment Reviews , vol.30 , Issue.3 , pp. 255-268
    • Thomas, S.M.1    Grandis, J.R.2
  • 49
    • 39149088612 scopus 로고    scopus 로고
    • Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck
    • DOI 10.1177/0091270007313393
    • Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J. Clin. Pharmacol. 48(3), 267-278 (2008). (Pubitemid 351257778)
    • (2008) Journal of Clinical Pharmacology , vol.48 , Issue.3 , pp. 267-278
    • Dirks, N.L.1    Nolting, A.2    Kovar, A.3    Meibohm, B.4
  • 51
    • 1842410784 scopus 로고    scopus 로고
    • Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients
    • DOI 10.1002/(SICI)1097-0142(19970515) 79:10<1879::AID-CNCR6>3.0. CO;2-B
    • Choi J-H, Oh JY, Ryu SK et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer 79(10), 1879-1883 (1997). (Pubitemid 27200369)
    • (1997) Cancer , vol.79 , Issue.10 , pp. 1879-1883
    • Choi, J.-H.1    Oh, J.Y.2    Ryu, S.K.3    Kim, S.J.4    Lee, N.Y.5    Kim, Y.S.6    Yi, S.Y.7    Shim, K.S.8    Han, W.S.9
  • 53
    • 70349658281 scopus 로고    scopus 로고
    • An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab
    • Cézé N, Ternant D, Piller F et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. Ther. Drug Monit. 31(5), 597-601 (2009).
    • (2009) Ther. Drug Monit , vol.31 , Issue.5 , pp. 597-601
    • Cézé, N.1    Ternant, D.2    Piller, F.3
  • 54
    • 0031903646 scopus 로고    scopus 로고
    • Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
    • Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16(8), 2659-2671 (1998). (Pubitemid 28363029)
    • (1998) Journal of Clinical Oncology , vol.16 , Issue.8 , pp. 2659-2671
    • Pegram, M.D.1    Lipton, A.2    Hayes, D.F.3    Weber, B.L.4    Baselga, J.M.5    Tripathy, D.6    Baly, D.7    Baughman, S.A.8    Twaddell, T.9    Glaspy, J.A.10    Slamon, D.J.11
  • 55
    • 63749132329 scopus 로고    scopus 로고
    • Utility of serum HER2 extracellular domain assessment in clinical decision making: Pooled analysis of four trials of trastuzumab in metastatic breast cancer
    • Lennon S, Barton C, Banken L et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J. Clin. Oncol. 27(10), 1685-1693 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.10 , pp. 1685-1693
    • Lennon, S.1    Barton, C.2    Banken, L.3
  • 56
    • 0032713216 scopus 로고    scopus 로고
    • Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    • Tokuda Y, Watanabe T, Omuro Y et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br. J. Cancer 81(8), 1419-1425 (1999).
    • (1999) Br. J. Cancer , vol.81 , Issue.8 , pp. 1419-1425
    • Tokuda, Y.1    Watanabe, T.2    Omuro, Y.3
  • 57
    • 0029991439 scopus 로고    scopus 로고
    • Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    • Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14(3), 737-744 (1996).
    • (1996) J. Clin. Oncol. , vol.14 , Issue.3 , pp. 737-744
    • Baselga, J.1    Tripathy, D.2    Mendelsohn J3
  • 59
    • 77955530237 scopus 로고    scopus 로고
    • Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation
    • Sageshima J, Ciancio G, Chen L, Burke GW. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics 3, 319-336 (2009).
    • (2009) Biologics , vol.3 , pp. 319-336
    • Sageshima, J.1    Ciancio, G.2    Chen, L.3    Burke, G.W.4
  • 60
    • 0028786730 scopus 로고
    • Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay
    • Fayer BE, Soni PP, Binger MH, Mould DR, Satoh H. Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. J. Immunol. Methods 186(1), 47-54 (1995).
    • (1995) J. Immunol. Methods , vol.186 , Issue.1 , pp. 47-54
    • Fayer, B.E.1    Soni, P.P.2    Binger, M.H.3    Mould, D.R.4    Satoh, H.5
  • 61
    • 38149076482 scopus 로고    scopus 로고
    • Serum soluble interleukin 2 receptor a in human cancer of adults and children: A review
    • Bien E, Balcerska A. Serum soluble interleukin 2 receptor a in human cancer of adults and children: a review. Biomarkers 13(1), 1-26 (2008).
    • (2008) Biomarkers , vol.13 , Issue.1 , pp. 1-26
    • Bien, E.1    Balcerska, A.2
  • 62
    • 0028226496 scopus 로고
    • Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias
    • Engelhard D, Nagler A, Singer R, Barak V. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias. Leuk Lymphoma 12(3-4), 273-280 (1994). (Pubitemid 24077177)
    • (1994) Leukemia and Lymphoma , vol.12 , Issue.3-4 , pp. 273-280
    • Engelhard, D.1    Nagler, A.2    Singer, R.3    Barak, V.4
  • 63
    • 17644382690 scopus 로고    scopus 로고
    • Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
    • DOI 10.1136/ard.2004.030452
    • Wolbink GJ, Voskuyl AE, Lems WF et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64(5), 704-707 (2005). (Pubitemid 40559296)
    • (2005) Annals of the Rheumatic Diseases , vol.64 , Issue.5 , pp. 704-707
    • Wolbink, G.J.1    Voskuyl, A.E.2    Lems, W.F.3    De Groot, E.4    Nurmohamed, M.T.5    Tak, P.P.6    Dijkmans, B.A.C.7    Aarden, L.8
  • 68
    • 65649090964 scopus 로고    scopus 로고
    • Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study
    • Loyet KM, Deng R, Liang W-C, Wu Y, Lowman HB, Deforge LE. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J. Immunol. Methods 345(1-2), 17-28 (2009).
    • (2009) J. Immunol. Methods , vol.345 , Issue.1-2 , pp. 17-28
    • Loyet, K.M.1    Deng, R.2    Liang, W.-C.3    Wu, Y.4    Lowman, H.B.5    Deforge, L.E.6
  • 69
    • 0023445565 scopus 로고
    • Radioimmunoassay of tumor necrosis factor in serum
    • Teppo AM, Maury CP. Radioimmunoassay of tumor necrosis factor in serum. Clin. Chem. 33(11), 2024-2027 (1987).
    • (1987) Clin. Chem. , vol.33 , Issue.11 , pp. 2024-2027
    • Teppo, A.M.1    Maury, C.P.2
  • 70
    • 67349158643 scopus 로고    scopus 로고
    • Widely varying TNF - A levels in patients with myasthenia gravis
    • Lee JS, Joo IS, Seok JI. Widely varying TNF-a levels in patients with myasthenia gravis. Neurol. Sci. 30(3), 259-262 (2009).
    • (2009) Neurol. Sci. , vol.30 , Issue.3 , pp. 259-262
    • Lee, J.S.1    Joo, I.S.2    Seok, J.I.3
  • 71
    • 0036188219 scopus 로고    scopus 로고
    • Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis
    • DOI 10.1002/art.10177
    • Straub RH, Paimela L, Peltomaa R, Schölmerich J, Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheumatism 46(3), 654-662 (2002). (Pubitemid 34214248)
    • (2002) Arthritis and Rheumatism , vol.46 , Issue.3 , pp. 654-662
    • Straub, R.H.1    Paimela, L.2    Peltomaa, R.3    Scholmerich, J.4    Leirisalo-Repo, M.5
  • 72
    • 34247344172 scopus 로고    scopus 로고
    • A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
    • DOI 10.1111/j.1365-2125.2006.02803.x
    • Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br. J. Clin. Pharmacol. 63(5), 548-561 (2007). (Pubitemid 46632569)
    • (2007) British Journal of Clinical Pharmacology , vol.63 , Issue.5 , pp. 548-561
    • Hayashi, N.1    Tsukamoto, Y.2    Sallas, W.M.3    Lowe, P.J.4
  • 73
    • 67650938578 scopus 로고    scopus 로고
    • Relationship between omalizumab pharmacokinetics IgE pharmacodynamics and symptoms in patients with severe persistent allergic IgE-mediated asthma
    • Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br. J. Clin. Pharmacol. 68(1), 61-76 (2009).
    • (2009) Br. J. Clin. Pharmacol. , vol.68 , Issue.1 , pp. 61-76
    • Lowe, P.J.1    Tannenbaum, S.2    Gautier, A.3    Jimenez, P.4
  • 75
    • 79953660097 scopus 로고    scopus 로고
    • Case studies: Free vs total ligand-binding PK assays to support monoclonal antibody therapeutic development
    • Presented at: Seattle WA USA
    • Yang J. Case studies: 'free' vs. 'total' ligand-binding PK assays to support monoclonal antibody therapeutic development. Presented at: 2009 AAPS National Biotechnology Conference. Seattle, WA, USA (2009).
    • (2009) 2009 AAPS National Biotechnology Conference
    • Yang, J.1
  • 76
    • 58149129505 scopus 로고    scopus 로고
    • Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations
    • e103
    • Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J. Allergy Clin. Immunol. 123(1), 107-113. e103 (2009).
    • (2009) J. Allergy Clin. Immunol. , vol.123 , Issue.1 , pp. 107-113
    • Slavin, R.G.1    Ferioli, C.2    Tannenbaum, S.J.3    Martin, C.4    Blogg, M.5    Lowe, P.J.6
  • 77
    • 33745771388 scopus 로고    scopus 로고
    • Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing
    • DOI 10.1097/01.iae.0000225354.92444.7a, PII 0000698220060500000004
    • Bakri SJ, Snyder MR, Pulido JS, McCannel CA, Weiss WT, Singh RJ. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. RETINA 26(5), 519-522 (2006). (Pubitemid 44620392)
    • (2006) Retina , vol.26 , Issue.5 , pp. 519-522
    • Bakri, S.J.1    Snyder, M.R.2    Pulido, J.S.3    McCannel, C.A.4    Weiss, W.T.5    Singh, R.J.6
  • 80
    • 33749647304 scopus 로고    scopus 로고
    • Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients
    • DOI 10.1097/01.iae.0000233327.68433.02, PII 0000698220061000000003
    • Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S.Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26(8), 871-876 (2006). (Pubitemid 44547438)
    • (2006) Retina , vol.26 , Issue.8 , pp. 871-876
    • Beer, P.M.1    Wong, S.J.2    Hammad, A.M.3    Falk, N.S.4    O'Malley, M.R.5    Khan, S.6
  • 81
    • 0032944081 scopus 로고    scopus 로고
    • Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease
    • DOI 10.1002/(SICI)1097-0142(19990101) 85:1<178::AID-CNCR25>3.0. CO;2-7
    • Kraft A, Weindel K, Ochs A et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85(1), 178-187 (1999). (Pubitemid 29031373)
    • (1999) Cancer , vol.85 , Issue.1 , pp. 178-187
    • Kraft, A.1    Weindel, K.2    Ochs, A.3    Marth, C.4    Zmija, J.5    Schumacher, P.6    Unger, C.7    Marme, D.8    Gastl, G.9
  • 82
    • 66649102432 scopus 로고    scopus 로고
    • Use of canakinumab in the cryopyrin-associated periodic syndrome
    • Lachmann HJ, Kone-Paut I, Kuemmerle- Deschner JB et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. New Engl.J. Med. 360(23), 2416-2425 (2009).
    • (2009) New Engl.J. Med. , vol.360 , Issue.23 , pp. 2416-2425
    • Lachmann, H.J.1    Kone-Paut, I.2    Kuemmerle-Deschner, J.B.3
  • 85
    • 0032479161 scopus 로고    scopus 로고
    • C5 convertase of the alternative pathway of complement
    • Rawal N, Pangburn MK. C5 convertase of the alternative pathway of complement. J. Biol. Chem. 273(27), 16828-16835 (1998).
    • (1998) J. Biol. Chem. , vol.273 , Issue.27 , pp. 16828-16835
    • Rawal, N.1    Pangburn, M.K.2
  • 88
    • 0034329326 scopus 로고    scopus 로고
    • A phase I/ II trial of iodine-131-tositumomab anti-CD20 etoposide cyclophosphamide and autologous stem cell transplantation for relapsed b-cell lymphomas
    • Press OW, Eary JF, Gooley T et al. A phase I/ II trial of iodine-131-tositumomab (anti- CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed b-cell lymphomas. Blood 96(9), 2934-2942 (2000).
    • (2000) Blood , vol.96 , Issue.9 , pp. 2934-2942
    • Press, O.W.1    Eary, J.F.2    Gooley, T.3
  • 89
    • 0036470439 scopus 로고    scopus 로고
    • Pharmacokinetics of CAMPATH-1H: Assay development and validation
    • DOI 10.1016/S0022-1759(01)00556-7, PII S0022175901005567
    • Rebello P, Hale G. Pharmacokinetics of campath-1h: assay development and validation. J. Immunol. Methods 260(1-2), 285-302 (2002). (Pubitemid 34132893)
    • (2002) Journal of Immunological Methods , vol.260 , Issue.1-2 , pp. 285-302
    • Rebello, P.1    Hale, G.2
  • 90
    • 4744371910 scopus 로고    scopus 로고
    • Alemtuzumab: Validation of a sensitive and simple enzyme-linked immunosorbent assay
    • DOI 10.1016/j.leukres.2004.04.003, PII S0145212604001274
    • Jilani I, Keating M, Giles FJ, O'brien S, Kantarjian HM, Albitar M. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leukemia Res. 28(12), 1255-1262 (2004). (Pubitemid 39314404)
    • (2004) Leukemia Research , vol.28 , Issue.12 , pp. 1255-1262
    • Jilani, I.1    Keating, M.2    Giles, F.J.3    O'Brien, S.4    Kantarjian, H.M.5    Albitar, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.